吉非替尼治疗非小细胞肺癌的疗效及其对EGFR表达的影响  

Efficacy of gefitinib and the effect of gefitinib on the expression of EGFR by in the treatment of non-small cell lung cancer

作　　者：刘小娟 张妙严 李玉菊 赵艾君 郑贸根 

机构地区：[1]开滦马家沟医院呼吸内科,河北唐山063021

出　　处：《海南医学》2013年第4期476-477,共2页Hainan Medical Journal

基　　金：河北省自然科学基金(编号:C2009001262);唐山市科学技术研究与发展计划卫生临床研究项目(编号:11150205A-12)

摘　　要：目的探讨吉非替尼治疗非小细胞肺癌的临床疗效,观察治疗后患者血清中表皮生长因子受体(EGFR)的表达。方法选取我院2010年7月至2011年7月收治的84例非小细胞肺癌患者,按患者入院先后顺序分为对照组与观察组,每组各42例,其中对照组患者采取常规化疗,观察组患者给予吉非替尼治疗。结果观察组患者治疗后有效率为45.24%,控制率为83.33%,均明显高于对照组的26.19%和59.52%;观察组患者血清中EGFR平均(11.33±4.12)ng/L,明显低于对照组的(19.28±4.68)ng/L,两组比较差异均具有统计学意义(P<0.05)。结论吉非替尼治疗非小细胞肺癌效果良好,可有效下调血清中EGFR的表达,值得临床推广应用。Objective To investigate the curative effect of Gefitinib and conventional chemotherapy for non-small cell lung cancer, and observed EGFR expression after treatment. Methods Eighty-four patients with non-small cell lung cancer were randomly divided into control group and the observation group from July 2010 to July 2011, with 42 cases in each group. The control group patients were taken conventional chemotherapy, and the observation group patients were given gefitinib. Results The effective rate of observation group was 45.24% and the control rate was 83.33%, significantly higher than those of the control group （26.19% and 59.52%）; the serum EGFR of observation group were （1.33±4.12） rig/L, significantly lower than that of the control group （19.28±4.68） ng/L （P〈0.05）. Conclusion Gefitinib has the good curative effect on non-small cell lung cancer, and can lower serum EGFR expression effectively.

关 键 词：吉非替尼 常规化疗 非小细胞肺癌 血清中表皮生长因子受体 

分 类 号：R734.2[医药卫生—肿瘤]